BPCR vs. KLSO, TV2H, KRM, WCW, ADA, ALGW, WINV, NBDG, TFG, and PEY
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Kelso Group (KLSO), Thames Ventures VCT 2 Healthcare Shs (TV2H), KRM22 (KRM), Walker Crips Group (WCW), Adams (ADA), Alpha Growth (ALGW), Worsley Investors (WINV), NB Distressed Debt New Glb (NBDG), Tetragon Financial (TFG), and Princess Private Equity (PEY). These companies are all part of the "asset management" industry.
Kelso Group (LON:KLSO) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
5.8% of Kelso Group shares are held by institutional investors. Comparatively, 41.2% of BioPharma Credit shares are held by institutional investors. 59.9% of Kelso Group shares are held by company insiders. Comparatively, 6.3% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Kelso Group's average media sentiment score of 1.20 beat BioPharma Credit's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.
BioPharma Credit has higher revenue and earnings than Kelso Group. BioPharma Credit is trading at a lower price-to-earnings ratio than Kelso Group, indicating that it is currently the more affordable of the two stocks.
BioPharma Credit has a net margin of 79.90% compared to BioPharma Credit's net margin of 59.53%. BioPharma Credit's return on equity of 39.82% beat Kelso Group's return on equity.
Kelso Group has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
BioPharma Credit received 84 more outperform votes than Kelso Group when rated by MarketBeat users.
Summary
BioPharma Credit beats Kelso Group on 7 of the 13 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
